Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice

European Journal of Pharmacology

Volumn 499, Issue 1-2, 2004, Pages 135-146

  Nielsen, Darci M ^a   Carey, Galen J ^a   Gold, Lisa H ^a  

^a PFIZER INC   (United States)

Author keywords

(Mouse); Antalarmin; Corticotropin releasing factor (CRF); Depression; DMP 696; DMP 904; Forced swim test; R 121919; Tail suspension test

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (3 PENTYLAMINO) 2,7 DIMETHYL 8 (2 METHYL 4 METHOXYPHENYL)PYRAZOLO[1,5 A]PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; AMITRIPTYLINE; ANTALARMIN; ANTIDEPRESSANT AGENT; CLORGYLINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DESIPRAMINE; DMP 904; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PYRIMIDINE DERIVATIVE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL MODEL; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THEORETICAL STUDY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLORGYLINE; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HINDLIMB SUSPENSION; MALE; MICE; MORPHOLINES; MOTOR ACTIVITY; PAROXETINE; PYRAZOLES; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SELEGILINE; SWIMMING; TRANYLCYPROMINE; TRIAZINES;

EID: 19344367932     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.091     Document Type: Article

References (78)

1. A. Alcaro, S. Cabib, R. Ventura, and S. Puglisi-Allegra Genotype- and experience-dependent susceptibility to depressive-like responses in the forced-swimming test Psychopharmacology (Berl.) 164 2002 138 143
2. F. Bai, X. Li, M. Clay, T. Lindstrom, and P. Skolnick Intra- and interstrain differences in models of "behavioral despair" Pharmacol. Biochem. Behav. 70 2001 187 192
3. T.L. Bale, and W.W. Vale Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses J. Neurosci. 23 2003 5295 5301
4. T.L. Bale, A. Contarino, G.W. Smith, R. Chan, L.H. Gold, P.E. Sawchenko, G.F. Koob, W.W. Vale, and K.F. Lee Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress Nat. Genet. 24 2000 410 414
5. C.W. Berridge, and A.J. Dunn A corticotropin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice Horm. Behav. 21 1987 393 401
6. F. Borsini Role of the serotonergic system in the forced swimming test Neurosci. Biobehav. Rev. 19 1995 377 395
7. F. Borsini, and A. Meli Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl.) 94 1988 147 160
8. M. Bourin, A.J. Fiocco, and F. Clenet How valuable are animal models in defining antidepressant activity? Hum. Psychopharmacol. 16 2001 9 21
9. D.R. Britton, G.F. Koob, J. Rivier, and W. Vale Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty Life Sci. 31 1982 363 367
10. R. Catalan, J.M. Gallart, J.M. Castellanos, and R. Galard Plasma corticotropin-releasing factor in depressive disorders Biol. Psychiatry 44 1998 15 20
11. A. Contarino, F. Dellu, G.F. Koob, G.W. Smith, K.F. Lee, W. Vale, and L.H. Gold Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1 Brain Res. 835 1999 1 9
12. S.C. Coste, R.A. Kesterson, K.A. Heldwein, S.L. Stevens, A.D. Heard, J.H. Hollis, S.E. Murray, J.K. Hill, G.A. Pantely, A.R. Hohimer, D.C. Hatton, T.J. Phillips, D.A. Finn, M.J. Low, M.B. Rittenberg, P. Stenzel, and M.P. Stenzel-Poore Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2 Nat. Genet. 24 2000 403 409
13. D.J. David, B.A. Nic Dhonnchadha, P. Jolliet, M. Hascoet, and M. Bourin Are there gender differences in the temperature profile of mice after acute antidepressant administration and exposure to two animal models of depression? Behav. Brain Res. 119 2001 203 211
14. D.J. David, C.E. Renard, P. Jolliet, M. Hascoet, and M. Bourin Antidepressant-like effects in various mice strains in the forced swimming test Psychopharmacology (Berl.) 166 2003 373 382
15. M.D. De Bellis, P.W. Gold, T.D. Geracioti Jr., S.J. Listwak, and M.A. Kling Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am. J. Psychiatry 150 1993 656 657
16. M.J. Detke, M. Rickels, and I. Lucki Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology (Berl.) 121 1995 66 72
17. A.J. Dunn, and C.W. Berridge Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15 1990 71 100
18. A.J. Dunn, and S.E. File Corticotropin-releasing factor has an anxiogenic action in the social interaction test Horm. Behav. 21 1987 193 202
19. R. Galard, R. Catalan, J.M. Castellanos, and J.M. Gallart Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test Biol. Psychiatry 51 2002 463 468
20. P.J. Gilligan, C. Baldauf, A. Cocuzza, D. Chidester, R. Zaczek, L.W. Fitzgerald, J. McElroy, M.A. Smith, H.S. Shen, J.A. Saye, D. Christ, G. Trainor, D.W. Robertson, and P. Hartig The discovery of 4-(3-pentylamino)-2,7-dimethyl- 8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin- releasing factor (hCRF1) antagonist Bioorg. Med. Chem. 8 2000 181 189
21. P.W. Gold, D.L. Loriaux, A. Roy, M.A. Kling, J.R. Calabrese, C.H. Kellner, L.K. Nieman, R.M. Post, D. Pickar, and W. Gallucci Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications N. Engl. J. Med. 314 1986 1329 1335
22. G. Griebel, G. Perrault, and D.J. Sanger Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone Psychopharmacology (Berl.) 138 1998 55 66
23. G. Griebel, J. Simiand, R. Steinberg, M. Jung, D. Gully, P. Roger, M. Geslin, B. Scatton, J.P. Maffrand, and P. Soubrie 4-(2-Chloro-4-methoxy-5- methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl] 5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist: II. Characterization in rodent models of stress-related disorders J. Pharmacol. Exp. Ther. 301 2002 333 345
24. L. Groenink, A. Dirks, P.M. Verdouw, M. Schipholt, J.G. Veening, G.J. van der, and B. Olivier HPA axis dysregulation in mice overexpressing corticotropin releasing hormone Biol. Psychiatry 51 2002 875 881
25. K.E. Habib, K.P. Weld, K.C. Rice, J. Pushkas, M. Champoux, S. Listwak, E.L. Webster, A.J. Atkinson, J. Schulkin, C. Contoreggi, G.P. Chrousos, S.M. McCann, S.J. Suomi, J.D. Higley, and P.W. Gold Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates Proc. Natl. Acad. Sci. U. S. A. 97 2000 6079 6084
26. S.E. Hammack, K.J. Richey, M.J. Schmid, M.L. LoPresti, L.R. Watkins, and S.F. Maier The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress J. Neurosci. 22 2002 1020 1026
27. L. He, P.J. Gilligan, R. Zaczek, L.W. Fitzgerald, J. McElroy, H.S. Shen, J.A. Saye, N.H. Kalin, S. Shelton, D. Christ, G. Trainor, and P. Hartig 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1, 5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist J. Med. Chem. 43 2000 449 456
28. S.C. Heinrichs, E.M. Pich, K.A. Miczek, K.T. Britton, and G.F. Koob Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action Brain Res. 581 1992 190 197
29. S.C. Heinrichs, J. Lapsansky, T.W. Lovenberg, E.B. De Souza, and D.T. Chalmers Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior Regul. Pept. 71 1997 15 21
30. S.C. Heinrichs, E.B. De Souza, G. Schulteis, J.L. Lapsansky, and D.E. Grigoriadis Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist Neuropsychopharmacology 27 2002 194 202
31. F. Holsboer The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety J. Psychiatr. Res. 33 1999 181 214
32. F. Holsboer, A. Gerken, U. von Bardeleben, W. Grimm, H. Beyer, O.A. Muller, and G.K. Stalla Human corticotropin-releasing hormone in depression-correlation with thyrotropin secretion following thyrotropin- releasing hormone Biol. Psychiatry 21 1986 601 611
33. M.E. Keck, T. Welt, A. Wigger, U. Renner, M. Engelmann, F. Holsboer, and R. Landgraf The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats Eur. J. Neurosci. 13 2001 373 380
34. T. Kishimoto, J. Radulovic, M. Radulovic, C.R. Lin, C. Schrick, F. Hooshmand, O. Hermanson, M.G. Rosenfeld, and J. Spiess Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2 Nat. Genet. 24 2000 415 419
35. M.A. Kling, T.D. Geracioti, J. Licinio, D. Michelson, E.H. Oldfield, and P.W. Gold Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings Psychopharmacol. Bull. 30 1994 489 494
36. G. Koob, S.C. Heinrichs, F. Menzaghi, E.M. Pich, and K.T. Britton Corticotropin releasing factor, stress and behavior Semin. Neurosci. 6 1994 221 229
37. S.M. Korte, G.A. Korte-Bouws, B. Bohus, and G.F. Koob Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats Physiol. Behav. 56 1994 115 120
38. G. Liebsch, R. Landgraf, R. Gerstberger, J.C. Probst, C.T. Wotjak, M. Engelmann, F. Holsboer, and A. Montkowski Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats Regul. Pept. 59 1995 229 239
39. G. Liebsch, R. Landgraf, M. Engelmann, P. Lorscher, and F. Holsboer Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain J. Psychiatr. Res. 33 1999 153 163
40. X. Liu, and H.K. Gershenfeld Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice Biol. Psychiatry 49 2001 575 581
41. I. Lucki, A. Dalvi, and A.J. Mayorga Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice Psychopharmacology (Berl.) 155 2001 315 322
42. J. Lundkvist, Z. Chai, R. Teheranian, H. Hasanvan, T. Bartfai, F. Jenck, U. Widmer, and J.L. Moreau A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity Eur. J. Pharmacol. 309 1996 195 200
43. C.M. Maciag, G. Dent, P. Gilligan, L. He, K. Dowling, T. Ko, S. Levine, and M.A. Smith Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation Neuropsychopharmacology 26 2002 574 582
44. R.S. Mansbach, E.N. Brooks, and Y.L. Chen Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist Eur. J. Pharmacol. 323 1997 21 26
45. F. Menzaghi, R.L. Howard, S.C. Heinrichs, W. Vale, J. Rivier, and G.F. Koob Characterization of a novel and potent corticotropin-releasing factor antagonist in rats J. Pharmacol. Exp. Ther. 269 1994 564 572
46. M.J. Millan, M. Brocco, A. Gobert, G. Dorey, P. Casara, and A. Dekeyne Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent Neuropsychopharmacology 25 2001 585 600
47. K. Momose, A. Inui, A. Asakawa, N. Ueno, M. Nakajima, M. Fujimiya, and M. Kasuga Intracerebroventricularly administered corticotropin-releasing factor inhibits food intake and produces anxiety-like behaviour at very low doses in mice Diabetes Obes. Metab. 1 1999 281 284
48. L. Naudon, M. El Yacoubi, J.M. Vaugeois, I. Leroux-Nicollet, and J. Costentin A chronic treatment with fluoxetine decreases 5-HT1A receptors labeling in mice selected as a genetic model of helplessness Brain Res. 936 2002 68 75
49. C.B. Nemeroff, E. Widerlov, G. Bissette, H. Walleus, I. Karlsson, K. Eklund, C.D. Kilts, P.T. Loosen, and W. Vale Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients Science 226 1984 1342 1344
50. C.B. Nemeroff, M.J. Owens, G. Bissette, A.C. Andorn, and M. Stanley Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims Arch. Gen. Psychiatry 45 1988 577 579
51. C.B. Nemeroff, G. Bissette, H. Akil, and M. Fink Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin Br. J. Psychiatry 158 1991 59 63
52. S. Okuyama, S. Chaki, N. Kawashima, Y. Suzuki, S. Ogawa, A. Nakazato, T. Kumagai, T. Okubo, and K. Tomisawa Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001 J. Pharmacol. Exp. Ther. 289 1999 926 935
53. M.J. Owens, and C.B. Nemeroff Physiology and pharmacology of corticotropin releasing factor Pharmacol. Rev. 43 1991 425 473
54. G. Perrault, E. Morel, B. Zivkovic, and D.J. Sanger Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice Pharmacol. Biochem. Behav. 42 1992 45 47
55. R.D. Porsolt Animal models of depression: utility for transgenic research Rev. Neurosci. 11 2000 53 58
56. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 1977 327 336
57. R.D. Porsolt, A. Bertin, and M. Jalfre "Behavioural despair" in rats and mice: strain differences and the effects of imipramine Eur. J. Pharmacol. 51 1978 291 294
58. F.C. Raadsheer, W.J. Hoogendijk, F.C. Stam, F.J. Tilders, and D.F. Swaab Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients Neuroendocrinology 60 1994 436 444
59. J. Radulovic, A. Ruhmann, T. Liepold, and J. Spiess Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2 J. Neurosci. 19 1999 5016 5025
60. T. Skutella, J.C. Probst, U. Renner, F. Holsboer, and C. Behl Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety Neuroscience 85 1998 795 805
61. G.W. Smith, J.M. Aubry, F. Dellu, A. Contarino, L.M. Bilezikjian, L.H. Gold, R. Chen, Y. Marchuk, C. Hauser, C.A. Bentley, P.E. Sawchenko, G.F. Koob, W. Vale, and K.F. Lee Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development Neuron 20 1998 1093 1102
62. M.P. Stenzel-Poore, S.C. Heinrichs, S. Rivest, G.F. Koob, and W.W. Vale Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior J. Neurosci. 14 1994 2579 2584
63. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology (Berl.) 85 1985 367 370
64. R.E. Sutton, G.F. Koob, M. Le Moal, J. Rivier, and W. Vale Corticotropin releasing factor produces behavioural activation in rats Nature 297 1982 331 333
65. N.R. Swerdlow, M.A. Geyer, W.W. Vale, and G.F. Koob Corticotropin- releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide Psychopharmacology 88 1986 147 152
66. N.R. Swerdlow, K.T. Britton, and G.F. Koob Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by a-helical CRF (9-41) Neuropsychopharmacology 2 1989 285 292
67. L.K. Takahashi, N.H. Kalin, J.A. Vanden Burgt, and J.E. Sherman Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats Behav. Neurosci. 103 1989 648 654
68. L.K. Takahashi, S.P. Ho, V. Livanov, N. Graciani, and S.P. Arneric Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety Brain Res. 902 2001 135 142
69. K. Takamori, N. Kawashima, S. Chaki, A. Nakazato, and K. Kameo Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test Pharmacol. Biochem. Behav. 69 2001 445 449
70. H. Takeuchi, S. Yatsugi, K. Hatanaka, K. Nakato, H. Hattori, R. Sonoda, K. Koshiya, M. Fujii, and T. Yamaguchi Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity Eur. J. Pharmacol. 329 1997 27 35
71. P. Timpl, R. Spanagel, I. Sillaber, A. Kresse, J.M. Reul, G.K. Stalla, V. Blanquet, T. Steckler, F. Holsboer, and W. Wurst Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 Nat. Genet. 19 1998 162 166
72. J.A. van der Heyden, E. Molewijk, and B. Olivier Strain differences in response to drugs in the tail suspension test for antidepressant activity Psychopharmacology (Berl.) 92 1987 127 130
73. M.M. van Gaalen, M.P. Stenzel-Poore, F. Holsboer, and T. Steckler Effects of transgenic overproduction of CRH on anxiety-like behaviour Eur. J. Neurosci. 15 2002 2007 2015
74. J.M. Vaugeois, G. Passera, F. Zuccaro, and J. Costentin Individual differences in response to imipramine in the mouse tail suspension test Psychopharmacology (Berl.) 134 1997 387 391
75. E.H. Wong, M.S. Sonders, S.G. Amara, P.M. Tinholt, M.F. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori, N. Carfagna, and R.A. McArthur Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol. Psychiatry 47 2000 818 829
76. M. Yamano, H. Yuki, S. Yasuda, and K. Miyata Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice J. Pharmacol. Exp. Ther. 292 2000 181 187
77. A.W. Zobel, T. Nickel, H.E. Kunzel, N. Ackl, A. Sonntag, M. Ising, and F. Holsboer Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J. Psychiatr. Res. 34 2000 171 181
78. E. Zorrilla, G. Valdez, J. Nozulak, G. Koob, and A. Markou Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat Brain Res. 952 2002 188